Business description
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Management board & Supervisory board
| CEO |
| Troy Wilson |
| Management board |
| Teresa Bair, Stephen Dale, Kathleen Ford, Brian Powl, Pete De Spain, Mollie Leoni, Roger Bakale, Francis Burrows, Tom Doyle |
| Supervisory board |
| Troy Wilson, Faheem Hasnain, Helen Collins, Thomas Malley, Diane Parks, Carol Schafer, Mary Szela |
Company data
| Name: |
Kura Oncology Inc. |
| Address: |
12730 High Bluff Drive Suite 400,San Diego, CA 92130 |
| Phone: |
+1 858 500 8800 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://kuraoncology.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
93.97% |
| IPO date: |
- |
Investor relations
| Name: |
Pete De Spain |
| IR phone: |
+1 858 500-8833 |
| IR Fax: |
- |
| IR e-mail: |
pete@kuraoncology.com
|
